Switch to Peter Gout's research page...

In Press

1. Dong X, Guan J, English J, Flint J, Yee J, Evans K, Murray N, MacAulay C, Ng R, Gout PW, Lam W, Laskin J, Ling V, Lam S, Wang YZ. Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy Clin. Cancer Research 2010 (In Press).
    Request Paper

2. Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer Curr Oncol 2010 (In Press).
    Request Paper

3. Pham A, Blower PE, Alvarado O, Ravula R, Gout PW, Huang Y. Pharmacogenomic approach reveals a role for the xc- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines J Pharmol Exp Ther 2009 (In Press).
    Request Paper

2009

4. Guan J, Lo M, Dockery P, Mahon S, Karp C, Buckley A, Lam S, Gout PW, Wang YZ. The x_c^- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: Use of sulfasalazine Cancer Chemotherapy and Pharmacology 2009;64:463-472. (2009).
    [View Abstract - PubMed 19104813]  Request Paper

5. Lo M, Wang YZ, Gout PW. Response to Savaskan NE et al. "The x_c^- cystine/glutamate antiporter-A potential target for therapy of cancer and other diseases: Yet another cytotoxic anticancer approach?" J Cell Physiol 2009;220(2):533-534. (2009).
    Request Paper

2008

6. Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, So A, Gout PW, Gleave M, Squire JA, Wang YZ. ASAP1, a Gene at 8q24, is Associated with Prostate Cancer Metastasis Cancer Research 68 p.4352-4359 (2008).
    [View Abstract - PubMed 18519696]  Request Paper

7. Lo M, Ling V, Wang YZ, Gout PW. The x_c^- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance Br J Cancer 99 p. 464-472 (2008).
    [View Abstract - PubMed 18648370]  Request Paper

8. Lo M, Wang YZ, Gout PW. The x_c^- Cystine/Glutamate Antiporter: a Potential Target for Therapy of Cancer and Other Diseases Journal of Cellular Physiology 215 p. 593-602 (2008).
    [View Abstract - PubMed 18181196]  Request Paper

2007

9. Doxsee DW, Gout PW*, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz J-C, Cunha GR, Wang, YZ.. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. The Prostate, 67(2): 162-171 (2007).
    [View Abstract - PubMed 17075799]  Request Paper

10. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of doxorubicin. Chemotherapy 53:210-217 (2007).
     [View Abstract - PubMed 17356269]  Request Paper

2006

11. J.C Cutz, J. Guan, J. Bayani, M. Yoshimoto, Hui Xue, M. Sutcliffe, J. English, J. Flint, J. LeRiche, J. Yee, J. Squire, P. W. Gout, S. Lam, Y.Z. Wang. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res, 12:4043-4054 (2006).
     [View Abstract - PubMed 16818704 ]  Request Paper

12. Ribela MTCP, Gout PW, de Oliveira JE, Bartolini P.. HPLC analysis of human pituitary hormones for pharmaceutical applications. Curr Pharm Anal 2(2):103-126 (2006).
     Request Paper

2005

13. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 96(1):48-55. (2005).
     [View Abstract - PubMed 15589579]  Request Paper

14. Peroni CN, Gout PW, Bartolini P. Animal models for growth hormone gene therapy. Curr Gene Ther 5(5):493-509. (2005).
     [View Abstract - PubMed 16250890]  Request Paper

15. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 85(11):1392-404. (2005).
     [View Abstract - PubMed 16155594]  Request Paper

2003

16. Gout PW, Simms CR, Robertson MC. In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anti-Cancer Drugs 14 (1): 21-29 (2003).
     [View Abstract - PubMed 12544255]  Request Paper

17. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res 23: 4571-4580 (2003).
     [View Abstract - PubMed 14981898]  Request Paper

18. Ribela MT, Gout PW, Bartolini P. Synthesis and chromatographic purification of recombinant human pituitary hormones. J Chromatogr B Analyt Technol Biomed Life Sci 790(1-2):285-316. (2003).
     [View Abstract - PubMed 12767339]  Request Paper

19. Ueda EKM, Gout PW, Morganti L. Current and prospective applications of metal ion-protein binding. J Chromatography A 988 (1): 1-23 (2003).
     [View Abstract - PubMed 12647817]  Request Paper

2001

20. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x_c^- cystine transporter: a new action for an old drug. Leukemia 15 (10):1633-1640 (2001).
     [View Abstract - PubMed 11587223]  Request Paper

21. Ueda EKM, Gout PW, Morganti L. Ni(II)-based immobilized metal ion affinity chromatography of recombinant human prolactin from periplasmic Escherichia coli extracts. J Chromatography A 922:165-75 (2001).
     [View Abstract - PubMed 11486861]  Request Paper

1999

22. Bode AM, Liang HQ, Green EH, Meyer TE, Buckley DJ, Norris A, Gout PW, Buckley AR. Ascorbic acid recycling in Nb2 lymphoma cells: implications for tumor progression. Free Radic Biol Med 26(1-2):136-47. (1999).
     [View Abstract - PubMed 9890649]  Request Paper

23. Too CK, Lee C, Sangster SM, Gout PW. Malignant progression of rat Nb2 lymphoma cells: chromosomal alterations and metastatic properties. Cancer Genet Cytogenet 110(2):115-23. (1999).
     [View Abstract - PubMed 10214359]  Request Paper

24. Zhang M, Blake MJ, Gout PW, Buckley DJ, Buckley AR. Proteolysis of heat shock transcription factor is associated with apoptosis in rat Nb2 lymphoma cells. Cell Growth Differ 10(11):759-67. (1999).
     [View Abstract - PubMed 10593652]  Request Paper

1998

25. Krumenacker JS, Buckley DJ, Leff MA, McCormack JT, de Jong G, Gout PW, Reed JC, Miyashita T, Magnuson NS, Buckley AR. Prolactin-regulated apoptosis of Nb2 lymphoma cells: pim-1, bcl-2, and bax expression. Endocrine 9(2):163-70. (1998).
     [View Abstract - PubMed 9867250]  Request Paper

26. Krumenacker JS, Montgomery DW, Buckley DJ, Gout PW, Buckley AR. Prolactin receptor signaling: shared components with the T-cell antigen receptor in Nb2 lymphoma cells. Endocrine 9(3):313-20. (1998).
     [View Abstract - PubMed 10221598]  Request Paper

27. Meyer TE, Liang HQ, Buckley AR, Buckley DJ, Gout PW, Green EH, Bode AM. Changes in glutathione redox cycling and oxidative stress response in the malignant progression of Nb2 lymphoma cells. Int J Cancer 77(1):55-63. (1998).
     [View Abstract - PubMed 9639394]  Request Paper

28. Morganti L, Soares CR, Affonso R, Gout PW, Bartolini P. Synthesis and characterization of recombinant, authentic human prolactin secreted into the periplasmic space of Escherichia coli. Biotechnol Appl Biochem 27 ( Pt 1):63-70. (1998).
     [View Abstract - PubMed 9477556]  Request Paper

1997

29. Buckley AR, Krumenacker JS, Buckley DJ, Leff MA, Magnuson NS, Reed JC, Miyashita T, de Jong G, Gout PW. Butyrate-induced reversal of dexamethasone resistance in autonomous rat Nb2 lymphoma cells. Apoptosis 2:518-28. (1997).
     [View Abstract - PubMed 14646523]  Request Paper

30. Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, Buckley AR. Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells. Leukemia 11(8):1329-37. (1997).
     [View Abstract - PubMed 9264389]  Request Paper

1996

31. Buckley AR, Leff MA, Buckley DJ, Magnuson NS, de Jong G, Gout PW. Alterations in pim-1 and c-myc expression associated with sodium butyrate-induced growth factor dependency in autonomous rat Nb2 lymphoma cells. Cell Growth Differ 7(12):1713-21. (1996).
     [View Abstract - PubMed 8959340]  Request Paper

32. Butnev VY, Gotschall RR, Baker VL, Moore WT, Gout PW, Bousfield GR. Glycosylated equine prolactin and its carbohydrate moiety. J Protein Chem 15(5):413-26. (1996).
     [View Abstract - PubMed 8895086]  Request Paper

33. Morganti L, Huyer M, Gout PW, Bartolini P. Production and characterization of biologically active Ala-Ser-(His)₆-Ile-Glu-Gly-Arg-human prolactin (tag-hPRL), secreted in the periplasmic space of Escherichia coli. Biotechnol Appl Biochem 23:67-75. (1996).
     [View Abstract - PubMed 8867898 ]  Request Paper

1995

34. Gilks CB, Porter SD, Barker C, Tsichlis PN, Gout PW. Prolactin (PRL)-dependent expression of a zinc finger protein-encoding gene, Gfi-1, in Nb2 lymphoma cells: constitutive expression in autonomous sublines. Endocrinology 136(4):1805-8. (1995).
     [View Abstract - PubMed 7895694]  Request Paper

1994

35. Buckley AR, Rao YP, Buckley DJ, Gout PW. Prolactin-induced phosphorylation and nuclear translocation of MAP kinase in Nb2 lymphoma cells. Biochem Biophys Res Commun 204(3):1158-64. (1994).
     [View Abstract - PubMed 7980591]  Request Paper

36. Gout PW, Horsman DE, Fox K, De Jong G, Ma S, Bruchovsky N. The rat Nb2 lymphoma: a novel model for tumor progression. Anticancer Res 14(6B):2485-92. (1994).
     [View Abstract - PubMed 7872671]  Request Paper

37. Livingstone VH, Gout PW, Crickmer SD, Fox K, Prior JC. Serum lactogens possessed normal bioactivity in patients with lactation insufficiency. Clin Endocrinol (Oxf) 41(2):193-8. (1994).
     [View Abstract - PubMed 7923823]  Request Paper

1993

38. Buckley AR, Buckley DJ, Gout PW, Liang H, Rao YP, Blake MJ. Inhibition by genistein of prolactin-induced Nb2 lymphoma cell mitogenesis. Mol Cell Endocrinol 98(1):17-25. (1993).
     [View Abstract - PubMed 8143910]  Request Paper

1992

39. Luck DN, Gout PW, Sutherland ER, Fox K, Huyer M, Smith M. Analysis of disulphide bridge function in recombinant bovine prolactin using site-specific mutagenesis and renaturation under mild alkaline conditions: a crucial role for the central disulphide bridge in the mitogenic activity of the hormone. Protein Eng 5(6):559-67. (1992).
     [View Abstract - PubMed 1438167]  Request Paper

1991

40. Horsman DE, Masui S, Gout PW. Karyotypic changes associated with loss of prolactin dependency of rat Nb2 node lymphoma cell cultures. Cancer Res 51(1):282-7. (1991).
     [View Abstract - PubMed 1988090]  Request Paper

41. Luck DN, Huyer M, Gout PW, Beer CT, Smith M. Single amino acid substitutions in recombinant bovine prolactin that markedly reduce its mitogenic activity in Nb2 cell cultures. Mol Endocrinol 5(12):1880-6. (1991).
     [View Abstract - PubMed 1791836]  Request Paper

1990

42. Luck DN, Gout PW, Kelsay K, Atkinson T, Beer CT, Smith M. Recombinant methionyl bovine prolactin: loss of bioactivity after single amino acid deletions from putative helical regions. Mol Endocrinol 4(7):1011-6. (1990).
     [View Abstract - PubMed 2284003]  Request Paper

43. Richards JF, Fox K, Peng T, Hsiao J, Gout PW. Inhibition of hormone-stimulated ornithine decarboxylase activity by lithium chloride. Life Sci 47(3):233-40. (1990).
     [View Abstract - PubMed 2167419]  Request Paper

1989

44. Emanuele NV, Azad N, Luckey JP, Engel J, Melone G, Metcalfe L, Gout PW, Beer CT, Kirsteins L, Lawrence AM. Presence of prolactin-like immunoreactivity and bioactivity in rat spinal cord. Neuroendocrinology 49(3):331-5. (1989).
     [View Abstract - PubMed 2716957]  Request Paper

45. Luck DN, Gout PW, Beer CT, Smith M. Bioactive recombinant methionyl bovine prolactin: structure-function studies using site-specific mutagenesis. Mol Endocrinol 3(5):822-31. (1989).
     [View Abstract - PubMed 2666850]  Request Paper

1988

46. Chapitis J, Riddick DH, Betz LM, Brumsted JR, Gibson M, Prior JC, Gout PW. Physicochemical characterization and functional activity of fibroid prolactin produced in cell culture. Am J Obstet Gynecol 158(4):846-53. (1988).
     [View Abstract - PubMed 3364497]  Request Paper

1987

47. Emanuele NV, Metcalfe L, Wallock L, Tentler J, Hagen TC, Beer CT, Martinson D, Gout PW, Kirsteins L, Lawrence AM. Extrahypothalamic brain prolactin: characterization and evidence for independence from pituitary prolactin. Brain Res 421(1-2):255-62. (1987).
     [View Abstract - PubMed 3690272]  Request Paper

48. Gout PW. Transient requirement for prolactin as a growth initiator following treatment of autonomous Nb2 node rat lymphoma cell cultures with butyrate. Cancer Res 47(7):1751-5. (1987).
     [View Abstract - PubMed 3815371]  Request Paper

49. Russell DH, Buckley AR, Montgomery DW, Larson NA, Gout PW, Beer CT, Putnam CW, Zukoski CF, Kibler R. Prolactin-dependent mitogenesis in Nb 2 node lymphoma cells: effects of immunosuppressive cyclopeptides. J Immunol 138(1):276-84. (1987).
     [View Abstract - PubMed 3097147]  Request Paper

1986

50. Buckley AR, Montgomery DW, Kibler R, Putnam CW, Zukoski CF, Gout PW, Beer CT, Russell DH. Prolactin stimulation of ornithine decarboxylase and mitogenesis in Nb2 node lymphoma cells: the role of protein kinase C and calcium mobilization. Immunopharmacology 12(1):37-51. (1986).
     [View Abstract - PubMed 3093404]  Request Paper

51. Emanuele NV, Metcalfe L, Wallock L, Tentler J, Hagen TC, Beer CT, Martinson D, Gout PW, Kirsteins L, Lawrence AM. Hypothalamic prolactin: characterization by radioimmunoassay and bioassay and response to hypophysectomy and restraint stress. Neuroendocrinology 44(2):217-21. (1986).
     [View Abstract - PubMed 3796795]  Request Paper

52. Gout PW, Noble RL, Beer CT. Cultured Nb rat lymphoma cells in endocrine and cancer research. Biochem Cell Biol 64(7):659-66. (1986).
     [View Abstract - PubMed 3755999]  Request Paper

53. Richards JF, Bishop PB, Peng T, Beer CT, Gout PW. An inhibitor of ornithine decarboxylase in lactogen-deprived Nb2 node rat lymphoma cells. Biochim Biophys Acta 883(3):542-51. (1986).
     [View Abstract - PubMed 3756220]  Request Paper

1985

54. Emerman JT, Leahy M, Gout PW, Bruchovsky N. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17(8):421-4. (1985).
     [View Abstract - PubMed 4054832]  Request Paper

55. Rennie PS, Prior JC, Bruchovsky N, Gout PW. Bioactive forms of serum lactogens: effects of treatment of prolactinoma patients with bromocriptine. Clin Endocrinol (Oxf) 22(1):65-73. (1985).
     [View Abstract - PubMed 3978829]  Request Paper

1984

56. Gout PW, Noble RL, Bruchovsky N, Beer CT. Vinblastine and vincristine--growth-inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells. Int J Cancer 34(2):245-8. (1984).
     [View Abstract - PubMed 6469399]  Request Paper

57. Gout PW, Tze WJ, Rennie PS, Bruchovsky N. Bioassay and radioimmunoassay of lactogens in sera from children. Clin Chim Acta 139(1):23-7. (1984).
     [View Abstract - PubMed 6373061]  Request Paper

1983

58. Shiu RP, Elsholtz HP, Tanaka T, Friesen HG, Gout PW, Beer CT, Noble RL. Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line. Endocrinology 113(1):159-65. (1983).
     [View Abstract - PubMed 6305632]  Request Paper

59. Tanaka T, Shishiba Y, Gout PW, Beer CT, Noble RL, Friesen HG. Radioimmunoassay and bioassay of human growth hormone and human prolactin. J Clin Endocrinol Metab 56(1):18-20. (1983).
     [View Abstract - PubMed 6401184]  Request Paper

1982

60. Hughes JP, Tanaka T, Gout PW, Beer CT, Noble RL, Friesen HG. Effect of iodination on human growth hormone and prolactin: characterized by bioassay, radioimmunoassay, radioreceptor assay, and electrophoresis. Endocrinology 111(3):827-32. (1982).
     [View Abstract - PubMed 7106054]  Request Paper

61. Richards JF, Beer CT, Bourgeault C, Chen K, Gout PW. Biochemical response of lymphoma cells to mitogenic stimulation by prolactin. Mol Cell Endocrinol 26(1-2):41-9. (1982).
     [View Abstract - PubMed 7084563]  Request Paper

1980

62. Gout PW, Beer CT, Noble RL. Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res 40(7):2433-6. (1980).
     [View Abstract - PubMed 6992985]  Request Paper

63. Noble RL, Beer CT, Gout PW. Evidence in vivo and in vitro of a role for the pituitary in the growth of malignant lymphomas in Nb rats. Cancer Res 40(7):2437-40. (1980).
     [View Abstract - PubMed 7388803]  Request Paper

64. Tanaka T, Shiu RP, Gout PW, Beer CT, Noble RL, Friesen HG. A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab 51(5):1058-63. (1980).
     [View Abstract - PubMed 7419681]  Request Paper

1978

65. Gout PW, Wijcik LL, Beer CT. Differences between vinblastine and vincristine in distribution in the blood of rats and binding by platelets and malignant cells. Eur J Cancer 14(11):1167-78. (1978).
     [View Abstract - PubMed 738324]  Request Paper

1977

66. Noble RL, Gout PW, Wijcik LL, Hebden HF, Beer CT. The distribution of ³H-vinblastine in tumor and host tissues of Nb rats bearting a transplantable lymphoma which is highly sensitive to the alkaloid. Cancer Res 37(5):1455-60. (1977).
     [View Abstract - PubMed 856464]  Request Paper

1973

67. Dunn BP, Gout PW, Beer CT. Effects of the antineoplastic alkaloid acronycine on nucleoside uptake and incorporation into nucleic acids by cultured L5178Y cells. Cancer Res 33(10):2310-9. (1973).
     [View Abstract - PubMed 4517733]  Request Paper

1971

68. Gout PW, Dunn BP, Beer CT. Effects of acronycine on nucleic acid synthesis and population growth in mammalian tumor cell cultures. J Cell Physiol 78(1):127-38. (1971).
     [View Abstract - PubMed 5286389]  Request Paper

1965

69. Voorma HO, Gout PW, van Duin J, Hoogendam BW, Bosch L. The read-out of turnip yellow mosaic virus ribonucleic acid as a polycistronic messenger in cell-free systems of Escherichia coli. Biochim Biophys Acta 95:446-60. (1965).
     [View Abstract - PubMed 14342537]  Request Paper

1964

70. Voorma HO, Gout PW, van Duin J, Hoogendam BW, Bosch L. Turnip yellow mosaic virus RNA: A polycistronic messenger for polypeptide synthesis by Escherichia coli ribosomes Biochim Biophys Acta 87:693-5. (1964).
     [View Abstract - PubMed 14220701]  Request Paper

1997

1. Buckley AR, Gout PW. Molecular and cellular mechanisms underlying the malignant progression of cancers. In: Peters & Peters, editors. Sourcebook on Asbestos Diseases vol 16. Charlottesville, VA: LEXIS, Division of Reed Elsevier. p. 45-79. (1997).
    Request Paper

1988

2. Gout PW, Beer CT, de Jong G, Rennie PS, Bruchovsky N. Prolactin-induced generation of transferrin-receptors: a critical event in the mitogenesis of lactogen-dependent Nb2 node rat lymphoma cells. In: Bresciani F, King RJB, Lippman ME, Raynaud J-P, editors. Hormones and Cancer 3, Progress in Cancer Research and Therapy vol 35. New York: Raven Press. p. 242-5. (1988).
    Request Paper

3. Luck DN, Gout PW, Beer CT, Smith M. Bioactive recombinant bovine prolactin: use of site-specific mutagenesis in structure-function analysis. In: Hoshino K, editor. Prolactin gene family and its receptors. Amsterdam: Elsevier Science Publishers BV; p. 99-106. (1988).
    [View Abstract - PubMed 2666850]  Request Paper

1987

4. Bruchovsky N, Rennie PS, Gout PW, Goldenberg SL. Endocrinology of Tumour progression. In: Engelsman E, de Koning Gans HJ, editors. Endocrine-related tumours, Proceedings of the 1985 International ICI-Farma Symposium in Noordwijkerhout, the Netherlands. Guildford: Update-Siebert Publications Ltd. p. 9-26. (1987).
    Request Paper

1985

5. Noble RL, Gout PW, Beer CT. Prolactin-dependent Nb rat lymphomas and their responses to hormones in vivo and in vitro. In: Hollander VP, editor. Hormonally responsive tumors. New York: Academic Press Inc. p. 63-91. (1985).
    Request Paper

1984

6. Gout PW. Ph.D. thesis: Nb rat lymphoma cell cultures - tools in endocrine and cancer research. State University of Leiden, The Netherlands (1984).
    Request Paper

2005

1. Gout PW, Kurita T, Doxsee D, Xue H, Wang YZ. Growth arrest by sulfasalazine (SASP) of subrenal capsule prostate cancer xenografts in immuno-deficient mice is coupled to a decrease in the number of tumor-associated macrophages. Proc Annu Meet Am Assoc Cancer Res (Anaheim, CA) Abstract No. 5865, p. 1380. (2005).
    Request Paper

2004

2. Gout PW and Wang YZ. The x_c^- cystine/glutamate antiporter as an anticancer target. Evaluation of the azocompound, sulfasalazine (SASP). Proceedings of the World Conference on Magic Bullets Celebrating Paul Ehrlich's 150th Birthday, Nuernberg, Germany, September 9-11, Abstract No. 172, page A-44. (2004).
    Request Paper

3. Gout PW, Doxsee D, Wang Y, Xue H, Cutz J, Bebb G, Wang YZ. Inhibition of human prostate cancer xenograft growth by sulfasalazine: a potential anticancer application for an old drug. 12th Int. Congress of Endocrinology (ICE2004; Lisbon, Portugal) Abstract No. P323, page 196. (2004).
    Request Paper

4. Gout PW, Guan J, Wang Y, Xue H, Doxsee DW, Sutcliffe M, Cutz JC, le Riche J, Bebb G, Lam S, Wang YZ. Potential use for sulfasalazine in lung cancer therapy. Proc Annu Meet Am Assoc Cancer Res (Orlando, FL) Abstract No. 3844. (2004).
    Request Paper

2003

5. Bebb G, Doxsee DW, Tucker C, Waterhouse DN, Williams ME, Masin D, Gascoyne RD, Wang Y, Gout PW. Sulfasalazine inhibits growth of mantle cell lymphoma (MCL) cell cultures via cyst(e)ine starvation and delays tumour growth in a newly developed murine MCL model. American Society of Hematology meeting. Blood 2003; 102 (11), Abstract No. 2401, p. 649a. (2003).
    Request Paper

6. Doxsee DW, Bebb G, Tucker C, Waterhouse DN, Masin D, Gout PW. Sulfasalazine-Induced Cyst(e)ine Starvation: A novel, potential approach for treatment of a variety of cancers. Proc Annu 85th Meet Endocrine Soc (Philadelphia) Abstract No. P2-448, p. 416. (2003).
    Request Paper

2002

7. Gout PW, Doxsee D, Robertson MC. Cyst(e)ine starvation of cancers: a novel therapeutic approach. Proc 7th World Congress Adv Oncology and 5th Int Symp Molec Med (Crete, Greece) in: Int J Molec Med 2002; 10 (Suppl 1): Abstract No. 167, p. S21. (2002).
    Request Paper

8. Gout PW, Robertson MC. Lymphoma growth-inhibitory activity of sulfasalazine (SASP) involves inhibition of cysteine supply by somatic cells. Predictive Oncology and Intervention Strategies conference (Paris, France). Cancer Detection and Prevention 2002; 26 (1): Abstract No. 456, p. S-176. (2002).
    Request Paper

9. Narang VS, Buckley DJ, Pauletti GM, Gout PW, Buckley AR. Increased reliance on the x_c^- cystine/glutamate antiporter with malignant progression of breast cancer. Proc Annu Meet Am Assoc Cancer Res (San Francisco) Abstract No. 2918, p. 589. (2002).
    Request Paper

2001

10. Gout PW, Hudon N, Simms CR. Use of sulfasalazine, a novel inhibitor of the x_c^- cystine transporter, in cyst(e)ine starvation of lymphoid cancers: intraperitoneal administration to rats leads to increased cystine/reduced cysteine plasma levels. Proc. AACR-NCI-EORTC Int Conf Molec Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications (Miami Beach, FL) Abstract No. 388, p. 80. (2001).
     Request Paper

11. Narang VS, Gout PW, Buckley DJ, Buckley AR. Antagonism of the x_c^- cystine/glutamate antiporter by sulfasalazine inhibits proliferation of human breast cancer cells Proc Annu Meet Am Assoc Cancer Res, p. 788 (2001).
     Request Paper

2000

12. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Novel lymphoma growth-inhibitory activity of the immunosuppressant, sulfasalazine Proc 11th Int Congress Endocrinology (Sydney, Australia), p. 313 (2000).
     Request Paper

13. Sadar MD, Bruchovsky N, Gout PW, Snoek R, Mawji NR. Androgen-independent increases in the expression of prostate-specific antigen can be inhibited by peptides mimicking sections of the N-terminus of the androgen receptor. Proc 11th Int Congress Endocrinology (Sydney, Australia) p. 310. (2000).
     Request Paper

1999

14. Gout PW, Buckley AR. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) at therapeutic levels on autonomous and prolactin-dependent Nb2 lymphoma culture growth. Proc Annu 80st Meet Endocrine Soc (San Diego) p. 303. (1999).
     Request Paper

1998

15. Bode AM, Liang HQ, Buckley AR, Buckley DJ, Gout PW. Genistein inhibits growth of prolactin-independent Nb2 lymphoma cells in vivo. Proc Annu 80th Meet Endocrine Soc (New Orleans) p. 370. (1998).
     Request Paper

16. Krumenacker JS, Buckley DJ, Montgomery DW, Gout PW, Buckley AR. Signaling cross-talk between prolactin and T-cell antigen receptors. Proc Annu 80th Meet Endocrine Soc (New Orleans) p. 309. (1998).
     Request Paper

17. Liang HQ, Bode AM, Buckley AR, Buckley DJ, Gout PW. Resistance to H₂O₂-induced apoptosis in prolactin-dependent and -independent Nb2 cells may be mediated by NFκB. Proc Annu 80th Meet Endocrine Soc (New Orleans) p. 370. (1998).
     Request Paper

1997

18. Buckley AR, Buckley DJ, Krumenacker JS, Leff MA, Laurie JA, Gout PW, de Jong G, Magnuson NS. Reversion of constitutive pim-1 expression to growth factor-dependency in rat Nb2 lymphoma and human B-CLL cells by butyrate. Proc Am Inst Cancer Res Dietary Fat and Cancer: Genetic and Molecular Interactions, New York: Plenum Press. p. 205. (1997).
     Request Paper

19. Buckley AR, Buckley DJ, Krumenacker JS, Leff MA, Magnuson NS, Reed JC, Miyashita T, de Jong G, Gout PW. Reversal of apoptosis resistance by butyrate in rat Nb2 lymphoma cells. Proc Annu Meet Am Assoc Cancer Res 38:p. 193. (1997).
     Request Paper

20. Gout PW. Progression of Nb2 lymphoma cells from hormonal dependency: association with increased cystine uptake via the x_c- transport system. Proc Annu 79th Meet Endocrine Soc (Minneapolis) p. 440. (1997).
     Request Paper

21. Liang HQ, Bode AM, Green EH, Buckley AR, Buckley DJ, Gout PW. Resistance to apoptosis in Nb2 lymphoma cells may be mediated by NF-κB. Proc Annu 4th Meet Oxygen Soc (San Francisco) p. 96. (1997).
     Request Paper

1996

22. Brown-Borg HM, Borg KE, Buckley DJ, Gout PW, Buckley AR. Adhesion molecule expression in PRL-dependent vs. -independent Nb2 lymphoma cells. Proc 10th Int Congress Endocrinol II:p. 933. (1996).
     Request Paper

23. Buckley AR, Leff MA, Buckley DJ, Magnuson NS, de Jong G, Gout PW. Inhibition by prolactin of dexamethasone-activated apoptosis in Nb2 lymphoma cells: a role for protooncogenes, pim-1 and bcl-2. Proc 10th Int Congress Endocrinol I:p. 99. (1996).
     Request Paper

24. Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, Buckley AR. Change in thiol growth requirement in the malignant progression of Nb2 lymphoma cells. Proc Annu Meet Am Assoc Cancer Res 37:p. 156. (1996).
     Request Paper

1995

25. Gout PW, Jabali MD, de Jong G, Fox K, Johnson P. Development of metastatic ability in Nb2 lymphoma cells is associated with increased amounts of H-ras protein and increased expression of CD44 at the cell surface. Proc Annu 77th Meet Endocrine Soc (Washington, DC) p. 279. (1995).
     Request Paper

1994

26. Gout PW, Fox K, Horsman DE, de Jong G, Bruchovsky N. Cultured rat Nb2 lymphoma cell lines provide a system for in vivo studies of progression of protein hormone-dependent, non-metastatic cancers to hormone- independent growth and metastasis. Proc Annu 76th Meet Endocrine Soc (Anaheim) p. 457. (1994).
     Request Paper

1993

27. Buckley AR, Buckley DJ, Gout PW, Liang H, Blake MJ. Inhibition of tyrosine kinase activity blocks mitogenesis and associated gene expression in prolactin-dependent and-independent Nb2 node lymphoma cells. Proc Annu 75th Meet Endocrine Soc (Las Vegas) p. 457. (1993).
     Request Paper

28. Gout PW, Gilks CB, Porter SD, Fox K, Barker C, Tsichlis, PN. Prolactin (PRL)-induced expression of a novel gene, Gfi-1, in PRL-dependent rat Nb2 node lymphoma cells: constitutive expression after development of PRL independence. Proc Annu 75th Meet Endocrine Soc (Las Vegas) p. 165. (1993).
     Request Paper

29. Huyer M, Luck DN, Gout PW, Smith M. Structure-function studies of bovine prolactin using site-specific mutagenesis. Proc 36th Meet Can Fed Biol Soc (Windsor) p. 34. (1993).
     Request Paper

1992

30. Gout PW, Gilks CB, Beer CT, Barker C, Porter SD, Tsichlis PN. Role for a novel, zinc finger protein encoding gene, Gfi-1, in the proliferation and malignant progression of prolactin (PRL)-dependent rat Nb2 lymphoma cells. Proc 9th Int Congress Endocrinology (Nice, France) Abstract No. 19-S04-048. (1992).
     Request Paper

31. Huyer M, Luck DN, Gout PW, Smith M. Structure-function studies of bovine prolactin using site-specific mutagenesis. Proc Protein Engng (Montreal) p. 24. (1992).
     Request Paper

1990

32. Gout PW, Horsman DE, Fox K, Beer CT. Loss of dependency on prolactin and increase in metastatic ability of Nb2 lymphoma cells are associated with well-defined karyotypic changes. Proc 15th Int Cancer Congress (Hamburg). J Cancer Res Clin Oncol 116 (Suppl):p. 225. (1990).
     Request Paper

1989

33. Fox K, Richards JF, Peng T, Gout PW. Effect of lithium on PRL-dependent ornithine decarboxylase activity in cultured Nb2 lymphoma cells. Proc Annu 71st Meet Endocrine Soc Abstract No. 1510. (1989).
     Request Paper

34. Horsman DE, Gout PW, de Jong G, Masui S, Noble RL. Karyotypic changes during the development of tetraploidy in a prolactin-independent Nb2 lymphoma cell line. Proc Annu Meet Am Assoc Cancer Res 30:Abstract No. 152. (1989).
     Request Paper

1988

35. Gout PW, Beer CT, Chin J, de Jong G, Noble RL. Emergence of a tetraploid line in Nb2 node rat lymphoma cell cultures. Proc 8th Int Congress Endocrinology (Kyoto, Japan) Abstract No. 05-22-074. (1988).
     Request Paper

36. Luck DN, Gout PW, Beer CT, Smith M. Bioactive recombinant bovine prolactin: use of site specific mutagenesis in structure-function analysis. Proc Vth Int Congress Prolactin (Kyoto, Japan) Abstract No. S6-5. (1988).
     Request Paper

1987

37. Gout PW. Evidence for a dual mitogenic activation pathway in autonomous, but prolactin (PRL)-sensitive Nb2 node rat lymphoma cells. Biology Growth Factors Meet (Banting and Best Diabetes Centre, Toronto) Abstract No. 41. (1987).
     Request Paper

38. Gout PW, Beer CT, de Jong G, Rennie PS, Bruchovsky N. Prolactin-induced generation of transferrin-receptors: a critical event in the mitogenesis of lactogen-dependent Nb2 node rat lymphoma cells. J Steroid Biochem 28 (Suppl): p. 141S. (1987).
     Request Paper

39. Gout, PW. Autonomous, but PRL-sensitive Nb2 node lymphoma cells: transient requirement for PRL as a growth initiator following treatment with sodium butyrate. Proc Annu 69th Meet Endocrine Soc Abstract No. 965. (1987).
     Request Paper

40. Luck DN, Gout PW, Beer CT, Smith M. Structure-function studies on bovine prolactin using oligonucleotide mutagenesis. Proc Symp Molec Biol Brain Endocrine Peptidergic Systems (Montreal) . (1987).
     Request Paper

1986

41. Emanuele NV, Engel JM, Melone G, Metcalfe L, Gout PW, Beer CT, Kirsteins L, Lawrence AM. Presence of prolactin-like immunoreactivity in rat spinal cord. Clin Res 34 (No. 2):p. 423A. (1986).
     Request Paper

42. Gout PW, de Jong G, Beer CT. Treatment of prolactin-independent Nb2 rat lymphoma cell cultures with sodium butyrate leads to a transient dependency on prolactin for growth. Proc 14th Int Cancer Congress (Budapest) Abstract No. 3646. (1986).
     Request Paper

1985

43. Emanuele NV, Metcalfe L, Wallock L, Tentler J, Hagen TC, Beer CT, Martinson, D, Gout PW, Kirsteins L, Lawrence AM. Brain-based prolactin: radioimmuno-assay, bioassay, ultracentrifugation, hypophysectomy and restraint stress. Clin Res 33 (No. 4):p. 874A. (1985).
     Request Paper

44. Gout PW, Bruchovsky N, Rennie PS, Beer CT. Prolactin markedly accelerates the recovery of butyrate-arrested cells of an autonomous Nb rat lymphoma subline. Clin Invest Med 8:Abstract No. C748. (1985).
     Request Paper

45. Gout PW, Bruchovsky N, Rennie PS, Beer CT. The resumption of growth of prolactin-independent Nb rat lymphoma cell cultures, which have been inhibited by sodium butyrate, is markedly stimulated by prolactin. Proc Annu 67th Meet Endocrine Soc Abstract No. 172. (1985).
     Request Paper

46. Russell DH, Kibler R, Montgomery DW, Gout PW, Beer CT, Zukoski CF. Cyclosporin and didemnin-B, novel immunosuppressive cyclopeptides, inhibit prolactin-dependent mitogenesis in Nb2 node lymphoma cells. J Leukocyte Biol 38:Abstract No. 346. (1985).
     Request Paper

1984

47. Emanuele N, Hagen T, Beer CT, Martinson D, Gout PW, Baker G, Kirsteins L, Lawrence AM. Brain prolactin: characterization by RIA, gel chromatography, and bioassay. Proc 7th Int Congress Endocrinology Abstract No. 311. (1984).
     Request Paper

48. Richards JF, Beer CT, Gout PW, Peng T, Bishop P. Occurrence of an inhibitor of ornithine decarboxylase (ODC) in rat lymphoid tissues. Proc Int Conference Polyamines (Hungary) Abstract No. 63. (1984).
     Request Paper

1983

49. Gout PW, Prior JC, Rennie PS, Bruchovsky N. Multiple forms of serum prolactin in hyperprolactinemia as shown by bioassay: effects of treatment with bromocriptine. J Steroid Biochem 19 (suppl):Abstract No. 418. (1983).
     Request Paper

50. Noble RL, Gout PW, Beer CT. The chemotherapeutic effectiveness of Vinca alkaloids against transplanted T-cell lymphomas in Nb rats is directly related to the hormonal status of the host. Proc Annu Meet Am Assoc Cancer Res 24: Abstract No. 1126. (1983).
     Request Paper

51. Richards JF, Peng T, Chan K, Beer CT, Gout PW. Ornithine decarboxylase (ODC) activity in extracts of proliferating prolactin-dependent Nb rat lymphoma cells is inhibited by extracts of cells in stationary growth phase. Proc Annu 65th Meet Endocrine Soc Abstract No. 85. (1983).
     Request Paper

1982

52. Beer CT, Noble RL, Gout PW. Vinblastine and vincristine - relative binding by lymphoma cells correlates with their differing cytotoxicities. Proc 13th Int Cancer Congress (UICC) Abstract No. 726. (1982).
     Request Paper

53. Noble RL, Gout PW, Beer. CT. Lymphomas originating at the transplant site of other tumors in Nb rats. Proc 13th Int Cancer Congress (UICC) Abstract No. 328. (1982).
     Request Paper

54. Noble RL, Gout PW, Beer CT. Prolactin-dependent Nb rat lymphomas may be made to progress - both in vivo and in vitro - towards hormonal autonomy. Proc Annu 64th Meet Endocrine Soc Abstract No. 867. (1982).
     Request Paper

55. Richards JF, Beer CT, Chen K, Gout PW. Biochemical events associated with mitogenic stimulation of Nb2 node rat lymphoma cells by prolactin. Proc Annu Meet Am Assoc Cancer Res 23:Abstract No. 903. (1982).
     Request Paper

1981

56. Emerman JT, Leahy M, Gout PW, Bruchovsky N. A possible role for growth hormone in human breast cancer. Clin Invest Med 4:24b. (1981).
     Request Paper

57. Leahy M, Emerman JT, Bruchovsky N, Tze WJ, Noble RL, Beer CT, Gout PW. Mitogenic activity of lactogenic hormones in sera from adults and children. Clin Invest Med 4:p. 15b. (1981).
     Request Paper

1980

58. Cowden EA, Friesen HG, Gout PW, Beer CT, Noble RL. Biologically active circulating prolactin (PRL) in uremia. Proc Can Soc Clin Invest;. (1980).
     Request Paper

59. Gout PW, Beer CT, Noble RL. Specific culture requirements, including prolactin (PRL), for a number of Nb rat lymphomas. Proc Annu Meet Am Assoc Cancer Res 21:Abstract No. 267. (1980).
     Request Paper

60. Tanaka T, Shiu RPC, Gout PW, Beer CT, Noble RL, Friesen HG. Rapid, sensitive and specific bioassay for lactogenic hormones using a lymphoma cell line. Proc Annu 62nd Meet Endocrine Soc Abstract No. 769. (1980).
     Request Paper

1979

61. Gout PW, Beer CT, Noble RL. Pituitary secretion stimulates growth of malignant lymphomas in Nb rats - evidence in vivo and in vitro. Proc Annu Meet Am Assoc Cancer Res 20: Abstract No. 106. (1979).
     Request Paper

1972

62. Gout PW, Dunn BP, Beer CT. Effects of acronycine on nucleic acid synthesis and precursor uptake by L5178Y cells. Fed Proc Abstract No. 31. (1972).
     Request Paper

1971

63. Dunn BP, Gout PW, Beer CT. Inhibition of population growth and nucleic acid synthesis in cultures of L5178Y and IRC cells by acronycine. Proc Annu Meet Am Assoc Cancer Res 12:Abstract No. 216. (1971).
     Request Paper

In Press

1. Ribela MTCP, Gout PW, de Oliveira JE, Bartolini P. HPLC analysis of human pituitary hormones for pharmaceutical applications Curr Pharm Anal 2006 (In Press).
    Request Paper